Vogl, U. Adding Androgen-Receptor Pathway Inhibition with Enzalutamide to Androgen Deprivation Therapy in Prostate Cancer Patients with High-Risk Biochemical Relapse: New Options, New Challenges. THE HEALTHBOOK COMPANY LTD.
Chicago Style (17th ed.) CitationVogl, Ursula. Adding Androgen-Receptor Pathway Inhibition with Enzalutamide to Androgen Deprivation Therapy in Prostate Cancer Patients with High-Risk Biochemical Relapse: New Options, New Challenges. THE HEALTHBOOK COMPANY LTD.
MLA (9th ed.) CitationVogl, Ursula. Adding Androgen-Receptor Pathway Inhibition with Enzalutamide to Androgen Deprivation Therapy in Prostate Cancer Patients with High-Risk Biochemical Relapse: New Options, New Challenges. THE HEALTHBOOK COMPANY LTD.
Warning: These citations may not always be 100% accurate.